Posters & Presentations

RYZ101-225Ac-DOTATATE-pembrolizumab-in-estrogen-receptor-thumb

RYZ101 (²²⁵Ac-DOTATATE) ± pembrolizumab in estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced and unresectable or metastatic breast cancer progressing after prior therapy: the Phase 1b/2 TRACY-1 study

San Antonio Breast Cancer Symposium 2024

68Ga-Ga-RAYZ-8009--A-Glypican-3–Targeted-Diagnostic-Radiopharmaceutical-for-Hepatocellular-Carcinoma-Molecular-Imaging—A-First-in-Human-Case-Series-thumb

[⁶⁸Ga]Ga-RAYZ-8009: A Glypican-3–Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging—A First-in-Human Case Series

JNM 2024

RayzeBio-WCLC-2024-Presentation-thumb

RYZ101 (²²⁵Ac-DOTATATE) + carboplatin + etoposide + atezolizumab in somatostatin receptor expressing extensive-stage small-cell lung cancer

2024 IASLC World Conference on Lung Cancer

RYZ101-301 ASCO 2024 ACTION-1 ORAL for SNMMI 03-Jun-2024 thumb

Phase 1b portion of the ACTION-1 phase 1b/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: Safety and efficacy findings

SNMMI Annual Meeting 2024

Phase-1b-portion-of-the-ACTION-1-phase-1b-3-trial-of-RYZ101-in-gastroenteropancreatic-neuroendocrine-tumors-progressing-after-177Lu-somatostatin-analog-therapy--Safety-and-efficacy-findings-thumb

Phase 1b portion of the ACTION-1 phase 1b/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analog therapy: Safety and efficacy findings

2024 ASCO Annual Meeting

Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors

2023 ESMO Congress

225Ac--DOTATATE-(RYZ101)-dosimetry-results-from-Part-1-of-the-ACTION-1-Trial-thumb

²²⁵Ac-DOTATATE (RYZ101) dosimetry results from Part 1 of the ACTION-1 Trial

2023 EANM Meeting

225ac-dotatae publication thumbnail

²²⁵Ac-DOTATATE (RYZ101) dosimetry results from Part 1 of the ACTION-1 Trial

2023 SNMMI Annual Meeting

neuroendocrine-tumors-progressing-after-177Lu-somatostatin-analogue-therapy--initial-safety-analysis-thumb

ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2 expressing gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: initial safety analysis

2023 ASCO Annual Meeting

GPC3-targeted-thumb

GPC3 targeted radiopharmaceutical therapy for HCC: Preclinical characterization of a novel peptide binder

2023 EASL Meeting

Anti-tumor activity of RYZ101 (Ac-225 DOTATATE) in somatostatin receptor-expressing preclinical models of small-cell lung cancer

2023 AACR Annual Meeting

Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant ²²⁵Ac-DOTATATE–Targeted α-Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome Study

JNM 2023